UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling

Oncogene, 2016-05, Vol.35 (20), p.2634-2644

2016

Volltextzugriff (PDF)

PDGF receptor kinase inhibitors for the treatment of restenosis

Cardiovascular research, 2005-02, Vol.65 (3), p.581-586

LEVITZKI, Alexander

2005

Volltextzugriff (PDF)

Cisplatin induces PKB Akt activation and p38 phosphorylation of the EGF receptor

Oncogene, 2006-11, Vol.25 (56), p.7381-7390

2006

Volltextzugriff (PDF)

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

Oncogene, 2010-11, Vol.29 (46), p.6149-6159

2010

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

Annual review of pharmacology and toxicology, 2013-01, Vol.53 (1), p.161-185

LEVITZKI, Alexander

2013

Volltextzugriff (PDF)

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling

Oncogene, 2016-05, Vol.35 (20), p.2675-2680

2016

Volltextzugriff (PDF)

Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress

Molecular and Cellular Biology, 2001-10, Vol.21 (20), p.6913-6926

2001

Volltextzugriff (PDF)

Substrate Competitive Inhibitors of IGF-1 Receptor Kinase

Biochemistry (Easton), 2000-12, Vol.39 (51), p.15705-15712

2000

Volltextzugriff (PDF)

Protein Kinase Inhibitors as a Therapeutic Modality

Accounts of chemical research, 2003-06, Vol.36 (6), p.462-469

Levitzki, Alexander

2003

Volltextzugriff (PDF)

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase

Biochemical pharmacology, 2006-05, Vol.71 (10), p.1422-1434

2006

Volltextzugriff (PDF)

Introduction: Signal transduction therapy—10 years later

Seminars in cancer biology, 2004-08, Vol.14 (4), p.219-221

Levitzki, A

2004

Volltextzugriff (PDF)

Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity

The Journal of biological chemistry, 2000-08, Vol.275 (32), p.24935-24944

2000

Volltextzugriff (PDF)

74 Targeting the Immune System to Cancer

European journal of cancer (1990), 2012-07, Vol.48, p.S18-S18

2012

Volltextzugriff (PDF)

Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents

Pharmacology & therapeutics (Oxford), 1999-05, Vol.82 (2), p.231-239

Levitzki, Alexander

1999

Volltextzugriff (PDF)

PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

Cytokine & growth factor reviews, 2004-08, Vol.15 (4), p.229-235

Levitzki, Alexander

2004

Volltextzugriff (PDF)

Tyrosine kinases as targets for cancer therapy

European journal of cancer (1990), 2002-09, Vol.38, p.S11-S18

Levitzki, Alexander

2002

Volltextzugriff (PDF)

ROS, stress-activated kinases and stress signaling in cancer

EMBO reports, 2002-05, Vol.3 (5), p.420-425

2002

Volltextzugriff (PDF)

The effect of tyrosine‐specific protein phosphorylation on the assembly of adherens‐type junctions

The EMBO journal, 1992-05, Vol.11 (5), p.1733-1742

1992

Volltextzugriff (PDF)

Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins

The Journal of biological chemistry, 1993-05, Vol.268 (15), p.11134-11142

1993

Volltextzugriff (PDF)

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

Journal of neurosurgery, 2001-09, Vol.95 (3), p.472-479

2001

Volltextzugriff (PDF)

Stochastic algorithm for kinase homology model construction

Current medicinal chemistry, 2004-03, Vol.11 (6), p.675-692

2004

Volltextzugriff (PDF)

Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor

Oncogene, 2006-11, Vol.25 (56), p.7381-7390

2006

Volltextzugriff (PDF)

EGF receptor as a therapeutic target

Lung cancer, 2003-08, Vol.41, p.9-14

Levitzki, Alexander

2003

Volltextzugriff (PDF)

β-adrenergic receptors and their mode of coupling to adenylate cyclase

Physiological reviews, 1986-07, Vol.66 (3), p.819-854

LEVITZKI, A

1986

Volltextzugriff (PDF)

Quinoxalines Versus Indolinones as Inhibitors of Restenosis

Circulation research, 2001-06, Vol.88 (12), p.e77-e77

Levitzki, Alexander

2001

Volltextzugriff (PDF)

1 – 25 von 527

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(481)
Mit Volltextzugriff
(428)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(334)
Life Sciences & Biomedicine
(287)
Animals
(212)
Humans
(151)
Biochemistry & Molecular Biology
(148)
Biological And Medical Sciences
(126)
Kinetics
(85)
Mice
(74)
Phosphorylation
(74)
Cell Biology
(68)
Medical Sciences
(65)
Protein-Tyrosine Kinases - Antagonists & Inhibitors
(65)
Fundamental And Applied Biological Sciences. Psychology
(61)
Adenylyl Cyclases - Metabolism
(50)
Pharmacology & Pharmacy
(49)
Pharmacology. Drug Treatments
(49)
Tyrphostins
(49)
Turkeys
(48)
Enzyme Inhibitors - Pharmacology
(47)
Oncology
(45)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Targeting colorectal cancer via its microenvironment by inhibiting IGF-1 receptor-insulin receptor substrate and STAT3 signaling

PDGF receptor kinase inhibitors for the treatment of restenosis

Cisplatin induces PKB Akt activation and p38 phosphorylation of the EGF receptor

Status of p53 in human cancer cells does not predict efficacy of CHK1 kinase inhibitors combined with chemotherapeutic agents

Tyrosine Kinase Inhibitors: Views of Selectivity, Sensitivity, and Clinical Performance

Targeting melanoma with NT157 by blocking Stat3 and IGF1R signaling

Enhanced ROS Production in Oncogenically Transformed Cells Potentiates c-Jun N-Terminal Kinase and p38 Mitogen-Activated Protein Kinase Activation and Sensitization to Genotoxic Stress

Substrate Competitive Inhibitors of IGF-1 Receptor Kinase

Protein Kinase Inhibitors as a Therapeutic Modality

Preclinical analysis of the analinoquinazoline AG1478, a specific small molecule inhibitor of EGF receptor tyrosine kinase

Introduction: Signal transduction therapy—10 years later

Activation of Stat3 in v-Src-transformed Fibroblasts Requires Cooperation of Jak1 Kinase Activity

74 Targeting the Immune System to Cancer

Protein Tyrosine Kinase Inhibitors as Novel Therapeutic Agents

PDGF receptor kinase inhibitors for the treatment of PDGF driven diseases

Tyrosine kinases as targets for cancer therapy

ROS, stress-activated kinases and stress signaling in cancer

The effect of tyrosine‐specific protein phosphorylation on the assembly of adherens‐type junctions

Selective inhibition of the epidermal growth factor and HER2/neu receptors by tyrphostins

Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor

Stochastic algorithm for kinase homology model construction

Cisplatin induces PKB/Akt activation and p38MAPK phosphorylation of the EGF receptor

EGF receptor as a therapeutic target

β-adrenergic receptors and their mode of coupling to adenylate cyclase

Quinoxalines Versus Indolinones as Inhibitors of Restenosis

Suchergebnisse filtern